본문으로 건너뛰기
cccskills
무료GitHub에 공개

endo-csii-suggest-t2dm-poor-control-despite-intensive

Suggests CSII with good adherence to monitoring and dosing for adults with type 2 diabetes mellitus who have poor glycemic control despite intensive insulin therapy, oral agents, other injectable therapy, and lifestyle modifications. Trigger phrases include 'T2DM on multiple injectables still uncontrolled' and 'Consider pump for insulin-requiring T2DM failing other therapies'.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

dromlakhani/MD2SKILL

실행 점수 미검증

설치 방법 보기

포함된 파일(1)

  • SKILL.md2.6 KB

SKILL.md(원문)

설치하기 전에 에이전트에게 전달되는 지시 내용을 확인할 수 있습니다.

Suggest CSII for T2DM with poor control despite intensive therapy

STEP 1 — Gather Information

Collect current regimen: insulin type/dose (basal-bolus MDI), oral agents (e.g., metformin), other injectables (GLP-1 RA, basal insulin), lifestyle changes, adherence, A1C, hypoglycemia episodes, glucose variability, patient willingness/ability to perform site changes and carb counting, education/support availability, comorbidities.

STEP 2 — Rule In / Rule Out

Is the patient on intensive insulin therapy (basal-bolus MDI) plus oral agents and/or other injectables with lifestyle modifications yet still has poor glycemic control (e.g., A1C >7.5‑8.0%)? If YES, proceed; if NO, optimize current therapy before considering CSII.

STEP 3 — Classify or Stratify

Assess suitability for CSII: adequate dexterity/vision, cognitive ability, willingness to perform frequent glucose monitoring, carbohydrate counting, and infusion site care; absence of uncontrolled psychiatric illness or substance abuse; reliable follow‑up access. Classify as suitable if criteria met.

STEP 4 — Decide

If suitable, initiate CSII with comprehensive education/training on pump operation, bolus calculator use, site rotation, and hypoglycemia/DKA prevention; schedule frequent follow‑up to review data and adjust settings.

Clinical Guardrails / Mimics / Pitfalls

Do not offer CSII to patients unable to perform self‑care tasks, lacking education/support, or with unrealistic expectations; avoid as first‑line before maximizing oral/GLP‑1/basal insulin; monitor for infusion site infections, lipohypertrophy, and DKA risk from pump failure; consider cost/access barriers.

Concrete Clinical Example

A 58‑year‑old on basal glargine 40 U qd, prandial lispro sliding scale, metformin 1000 mg BID, liraglutide 1.8 mg daily, with A1C 9.2% despite adherence, is motivated, passes carb‑counting and site‑care assessment, and has regular follow‑up; CSII is suggested with training.

Source: Diabetes Technology—Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults, Endocrine Society, 2016, DOI:10.1210/jc.2016-2534

리뷰

아직 리뷰가 없습니다. 사용해 본 소감을 남겨 주세요.

댓글

로그인 없이 쓸 수 있습니다. 사용 후기, 질문, 작동하지 않은 환경 등을 편하게 남겨 주세요.

아직 댓글이 없습니다. 첫 댓글을 남겨 보세요.

보내면 바로 공개됩니다. 이메일 주소나 전화번호 같은 개인 정보는 쓰지 마세요. URL은 2개까지입니다.

0 / 1,000자

이 양식은 reCAPTCHA로 보호되며 Google 개인정보처리방침 및 서비스 약관이 적용됩니다.

같은 저장소의 스킬

780g-pump-adjustment

무료

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

dromlakhani/MD2SKILL142026년 10월 20일 업데이트

ata-acth-stim-test-interpretation

무료

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

dromlakhani/MD2SKILL142026년 10월 20일 업데이트

ata-adrenal-crisis-treatment

무료

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

dromlakhani/MD2SKILL142026년 10월 20일 업데이트

ata-aed-ai-education

무료

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

dromlakhani/MD2SKILL142026년 10월 20일 업데이트

ata-aed-lt4-monitoring

무료

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

dromlakhani/MD2SKILL142026년 10월 20일 업데이트

ata-cortisol-cutoff-ai-diagnosis

무료

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

dromlakhani/MD2SKILL142026년 10월 20일 업데이트

dromlakhani의 스킬 모두 보기

이 스킬의 문제 신고